Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment ...
Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune ...
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy ...
Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR ...
HIV-1 envelope glycoprotein (Env), a gp120–gp41 trimer, undergoes coordinated conformational changes that drive membrane fusion and allow immune evasion by transiently concealing ...
Researchers created a human spinal cord organoid, injured it, then applied an experimental therapy. What happened next was ...
In an interview with Targeted Oncology, Naomi Haas, MD, discusses the evolving landscape of adjuvant and neoadjuvant immune ...
A study published in Cell Research advances a central idea in stem cell biology by identifying a checkpoint that controls the ...
AIRE has been well known to contribute to immune self-tolerance in the thymus by expressing auto-antigens; in this manuscript, the authors describe unexpected findings about the interaction of AIRE ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite promising immunotherapy, response rates remain suboptimal. Tumour-associated ...
In a new paper published in Cancer Research, researchers at MUSC Hollings Cancer Center have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results